Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
University of Colorado Denver
mi
from
Aurora, CO
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
Northwestern University-Comprehensive Transplant Center
mi
from
Chicago, IL
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
Northwestern University-Comprehensive Transplant Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
The University of Chicago Medical Center - Kindney Trasnplant - Nephrology
mi
from
Chicago, IL
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
The University of Chicago Medical Center - Kindney Trasnplant - Nephrology
mi
from
Chicago, IL
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine
mi
from
Minneapolis, MN
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
Mayo Clinic, Rochester - Infectious Diseases
mi
from
Rochester, MN
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
Mayo Clinic, Rochester - Infectious Diseases
mi
from
Rochester, MN
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
Dartmouth-Hitchcock Medical Center - Infectious Disease
mi
from
Lebanon, NH
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
Dartmouth-Hitchcock Medical Center - Infectious Disease
mi
from
Lebanon, NH
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
Dallas Nephrology Associates and Dallas Transplant Institute
mi
from
Dallas, TX
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
Dallas Nephrology Associates and Dallas Transplant Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
University of Washington Medicine
mi
from
Seattle, WA
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
University of Washington Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated:  2/28/2013
University of Wisconsin Hospital and Clinics - Clinical Science Center - Nephrology
mi
from
Madison, WI
Cidofovir in Renal Transplant Recipients With BKVN
A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Status: Enrolling
Updated: 2/28/2013
University of Wisconsin Hospital and Clinics - Clinical Science Center - Nephrology
mi
from
Madison, WI
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Barnes Jewish Dialysis Center
mi
from
St. Louis, MO
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Barnes Jewish Dialysis Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Circle Medical Management
mi
from
Chicago, IL
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Circle Medical Management
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
DaVita Bluemound Home Dialysis
mi
from
Wauwatosa, WI
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
DaVita Bluemound Home Dialysis
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
DaVita Grapevine at Home
mi
from
Grapevine, TX
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
DaVita Grapevine at Home
mi
from
Grapevine, TX
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Dialysis Center of Lincoln
mi
from
Lincoln, NE
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Dialysis Center of Lincoln
mi
from
Lincoln, NE
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Indiana University Dialysis Center
mi
from
Indianapolis, IN
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Indiana University Dialysis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Kansas Nephrology Research Institute, LLC
mi
from
Wichita, KA
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Kansas Nephrology Research Institute, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Rubin Dialysis
mi
from
Saratoga Springs, NY
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Rubin Dialysis
mi
from
Saratoga Springs, NY
Click here to add this to my saved trials
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated:  3/1/2013
Satellite Healthcare/Wellbound
mi
from
San Jose, CA
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Status: Enrolling
Updated: 3/1/2013
Satellite Healthcare/Wellbound
mi
from
San Jose, CA
Click here to add this to my saved trials
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
Status: Enrolling
Updated:  3/1/2013
Southwest Clinical Research Institute
mi
from
Tempe, AZ
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
Status: Enrolling
Updated: 3/1/2013
Southwest Clinical Research Institute
mi
from
Tempe, AZ
Click here to add this to my saved trials
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
Status: Enrolling
Updated:  3/1/2013
Denver Nephrology
mi
from
Denver, CO
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
Status: Enrolling
Updated: 3/1/2013
Denver Nephrology
mi
from
Denver, CO
Click here to add this to my saved trials
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
Status: Enrolling
Updated:  3/1/2013
DaVita Clinical Research
mi
from
Minneapolis, MN
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis
Status: Enrolling
Updated: 3/1/2013
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency
An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics
Status: Enrolling
Updated:  3/12/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency
An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics
Status: Enrolling
Updated: 3/12/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 1049
mi
from
San Diego, CA
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 1049
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 000012
mi
from
San Francisco, CA
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 000012
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 007
mi
from
Aurora, CO
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 007
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 000002
mi
from
Tampa, FL
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 000002
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 004
mi
from
Lexington, KY
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 004
mi
from
Lexington, KY
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 000009
mi
from
Ann Arbor, MI
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 000009
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 000010
mi
from
Livingston, NJ
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 000010
mi
from
Livingston, NJ
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 000011
mi
from
Buffalo, NY
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 000011
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 00006
mi
from
New York, NY
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 00006
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 00008
mi
from
Cleveland, OH
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 00008
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 00003
mi
from
Philadelphia, PA
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 00003
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 000013
mi
from
Dallas, TX
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 000013
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated:  3/15/2013
Clinical Investigative Site 00001
mi
from
Charlottesville, VA
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Status: Enrolling
Updated: 3/15/2013
Clinical Investigative Site 00001
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  4/22/2013
Clinical Research Facility
mi
from
Tampa, FL
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 4/22/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  4/22/2013
Clinical Research Facility
mi
from
Minneapolis, MN
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 4/22/2013
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  4/22/2013
Clinical Research Facility
mi
from
Knoxville, TN
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 4/22/2013
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Care Transitions in Renal Disease Patients
Care Transitions in Renal Disease Patients
Status: Enrolling
Updated:  4/25/2013
Fresenius
mi
from
Franklin, TN
Care Transitions in Renal Disease Patients
Care Transitions in Renal Disease Patients
Status: Enrolling
Updated: 4/25/2013
Fresenius
mi
from
Franklin, TN
Click here to add this to my saved trials
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Status: Enrolling
Updated:  5/13/2013
University of Utah
mi
from
Salt Lake City, UT
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Status: Enrolling
Updated: 5/13/2013
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Using Continuous Positive Airway Pressure to Reduce the Incidence of Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease
Using CPAP to Prevent Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease
Status: Enrolling
Updated:  5/17/2013
Tampa General Hospital
mi
from
Tampa, FL
Using Continuous Positive Airway Pressure to Reduce the Incidence of Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease
Using CPAP to Prevent Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease
Status: Enrolling
Updated: 5/17/2013
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Adherence Enhancement for Renal Transplant Patients
Adherence Enhancement for Renal Transplant Patients
Status: Enrolling
Updated:  5/17/2013
Medical University of South Carolina
mi
from
Charleston, SC
Adherence Enhancement for Renal Transplant Patients
Adherence Enhancement for Renal Transplant Patients
Status: Enrolling
Updated: 5/17/2013
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
The Effect of Therapeutic Hypothermia on Deceased Donor Renal Graft Outcomes - a Randomized Controlled Trial From the Region 5 Donor Management Goals Workgroup
Status: Enrolling
Updated:  5/28/2013
University of California - San Francisco
mi
from
San Francisco, CA
The Effect of Therapeutic Hypothermia on Deceased Donor Renal Graft Outcomes - a Randomized Controlled Trial From the Region 5 Donor Management Goals Workgroup
Status: Enrolling
Updated: 5/28/2013
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
"Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study"
Status: Enrolling
Updated:  5/30/2013
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
"Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study"
Status: Enrolling
Updated: 5/30/2013
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Predictors and Intervention for Noncompliance
Predictors and Intervention for Noncompliance
Status: Enrolling
Updated:  6/28/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Predictors and Intervention for Noncompliance
Predictors and Intervention for Noncompliance
Status: Enrolling
Updated: 6/28/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx)
Status: Enrolling
Updated:  7/10/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx)
Status: Enrolling
Updated: 7/10/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-
Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact
Status: Enrolling
Updated:  7/29/2013
Cleveland Clinic
mi
from
Cleveland, OH
Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-
Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact
Status: Enrolling
Updated: 7/29/2013
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease
Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease
Status: Enrolling
Updated:  7/29/2013
Cleveland Clinic
mi
from
Cleveland, OH
Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease
Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease
Status: Enrolling
Updated: 7/29/2013
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery
MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery
Status: Enrolling
Updated:  8/6/2013
Barnes-Jewish Hospital
mi
from
St.Louis, MO
MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery
MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery
Status: Enrolling
Updated: 8/6/2013
Barnes-Jewish Hospital
mi
from
St.Louis, MO
Click here to add this to my saved trials
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients
Status: Enrolling
Updated:  8/16/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients
Status: Enrolling
Updated: 8/16/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials